We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

New MRI-Guided Therapy Navigates Magnetic Seed Through Brain to Heat and Destroy Tumors

By HospiMedica International staff writers
Posted on 03 Feb 2022
Image: Minimally Invasive Image-Guided Ablation (Photo courtesy of University College London)
Image: Minimally Invasive Image-Guided Ablation (Photo courtesy of University College London)

Scientists have developed a novel cancer therapy that uses an MRI scanner to guide a magnetic seed through the brain to heat and destroy tumors.

The therapy, demonstrated by scientists at University College London (London, UK), in mice, is called “minimally invasive image-guided ablation” or MINIMA and comprises a ferromagnetic thermoseed navigated to a tumor using magnetic propulsion gradients generated by an MRI scanner, before being remotely heated to kill nearby cancer cells. The researchers say their findings establish ‘proof-of-concept’ for precise and effective treatment of hard-to-reach glioblastoma, along with other cancers such as prostate, that could benefit from less invasive therapies.

In the study, the UCL team demonstrated the three key components of MINIMA to a high level of accuracy: precise seed imaging; navigation through brain tissue using a tailored MRI system, tracked to within 0.3 mm accuracy; and eradicating the tumor by heating it in a mouse model. Ferromagnetic thermoseeds are spherical in shape, 2 mm in size and are made of a metal alloy; they are implanted superficially into tissue before being navigated to the cancer. MRI scanners are readily available in hospitals around the world and are pivotal in the diagnosis of diseases such as cancer. The work at UCL shows that MINIMA has the potential to elevate an MRI scanner from a diagnostic device to a therapeutic platform.

“MINIMA is a new MRI-guided therapy that has the potential to avoid traditional side effects by precisely treating the tumor without harming healthy tissues,” said senior author, Professor Mark Lythgoe (UCL Centre for Advanced Biomedical Imaging). “Because the heating seed is magnetic, the magnetic fields in the MRI scanner can be used to remotely steer the seed through tissue to the tumor. Once at the tumor, the seed can then be heated, destroying the cancer cells, while causing limited damage to surrounding healthy tissues.”

“Using an MRI scanner to deliver a therapy in this way allows the therapeutic seed and the tumor to be imaged throughout the procedure, ensuring the treatment is delivered with precision and without having to perform open surgery,” added lead author, Rebecca Baker, (UCL Centre for Advanced Biomedical Imaging). “This could be beneficial to patients by reducing recovery times and minimizing the chance of side effects.”

Related Links:
University College London 

Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Half Apron
Demi
New
Measuring Rod
seca 233

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more